Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930059 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT00930059 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 191 participants.
The verdict
NCT00930059, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.
Interventions
- DRUG Placebo
- DRUG PF-04447943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2009-09-10 |
| Est. Completion | 2010-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00930059
The ClinicalTrials.gov registry entry for NCT00930059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00930059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00930059 about?
NCT00930059 is a clinical study titled "A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease". The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course ...
What is the current status of trial NCT00930059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2009-09-10. Estimated completion is 2010-09-22.
What interventions are being tested in trial NCT00930059?
The interventions under investigation include: Placebo (DRUG), PF-04447943 (DRUG).
Who is sponsoring clinical trial NCT00930059?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.